亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Dihydroquinazoline-Derived Inhibitors for Alzheimer's Disease Treatment

總結: Researchers at Purdue University have developed novel compounds that inhibit beta-secretase for Alzheimer's treatment. By focusing on a known dihydroquinazoline scaffold, a series of novel dihydroquinazoline derivatives were synthesized and evaluated. Several compounds in this series were shown to exhibit better beta-secretase cellular inhibitory activity compared to current compounds reported in literature. These compounds show increased potency, improved aqueous solubility, increased metabolic stability, and improved oral bioavailability.

技術優勢: Improved beta-secretase cellular inhibitionIncreased metabolic stability

*Background: Alzheimer's disease is a progressive mental deterioration, resulting in loss of memory, confusion and disorientation, and other behavioral problems. Unfortunately, no definitive cure has been developed to treat this disease. Beta-secretase, an important enzyme in the development and onset of Alzheimer's disease, contributes to the formation of amyloid-beta peptides that aggregate in the brain of Alzheimer's patients. Blocking beta-secretase is a potential strategy for the treatment of Alzheimer's disease.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry

欲了解更多信息，請點擊這裡